Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
Operating under our Biopharm Division and Neuromodulation Division, Vivani develops, manufactures, and markets therapies that target chronic conditions with high unmet medical needs.
Our primary focus is advancing our portfolio of novel, long-term drug implant candidates by leveraging our proprietary NanoPortal technology to address medication adherence and help patients realize the full potential benefits of their medicines.
Our proprietary NanoPortal implant technology is designed to deliver medication steadily over extended periods of time, with the aim of guaranteeing that patients consistently receive the right dose while avoiding potential safety concerns associated with medications with fluctuating drug release profiles. Unlike other extended-release therapeutic implants, NanoPortal can also deliver large hydrophilic molecules, such as peptides and proteins, potentially enabling a broader range of therapeutic applications.
Leveraging our NanoPortal technology, we are developing a portfolio of innovative, highly differentiated drug candidates that target Type 2 diabetes, Non-Alcoholic Steatohepatitis (NASH) and obesity. We are also developing a product to treat overweight companion cats with feline diabetes and pre-diabetes.
NPM-119 is a miniature, subdermal, exenatide drug implant candidate with the potential to treat the growing number of patients with Type 2 diabetes. This small device can be conveniently inserted by a healthcare professional during a quick outpatient procedure and can provide steady doses of medication for up to six months, freeing patients from the hassles of taking a daily pill or a weekly injection.
We are currently preparing to initiate a study to evaluate NPM-119 over a 12-week duration. In order to begin the proposed clinical study, we plan to file an Investigational New Drug application with the U.S. FDA in early 2023.